Clive, Jan. 18, 2023 (GLOBE NEWSWIRE) -- Clive, Iowa -
Dylan Gemelli, the expert voice behind the PE Fitness YouTube channel, is offering his viewers the best information about SARMs, performance enhancement compounds, diet, training, and everything and anything health and fitness related.
In his videos, Dylan stresses the importance of health, and longevity and teaches everyone that not only is fitness a marathon and not a sprint, but also the importance of getting the information they NEED to hear and not just what they want to hear. Readers interested in supplementing their fitness with SARMs and similar compounds, who also care deeply about these aspects, should consider subscribing to his channel.
Dylan Gemelli is a world-renowned NASM-certified Personal Trainer, Fitness Nutrition Expert, Weight Loss Expert, and Group Fitness Instructor. The PE Fitness YouTube channel, which covers SARMs and a plethora of related topics such as anabolic steroids, SARMs cycles, diet and nutrition, health and longevity, peptides, supplements, training, bodybuilding, and more, is one of the highest volume channels of its kind in the health and fitness world.
Dylan Gemelli began his YouTube journey in late 2012, discussing performance-enhancing drugs as well as his focus on general health, fitness, and diet on his previous channel Elite Fitness. Soon, the wealth of information he offered his viewers and his consistent upload schedule paid off as he amassed over 200,000 subscribers by 2018. His content particularly resonated with his audience because of his penchant for telling them the whole truth about using SARMs and other performance-enhancing compounds that many influencers in the industry are not willing to share.
His honest attitude towards SARMs and anabolic steroids, which still get a bad rap in the fitness industry to some extent, kept his audience coming back and interested in his advice and point of view. While spending his time educating people on performance-enhancing drugs, he also often spoke out against the reckless use of SARMs and similar fitness supplements. To reach out to his viewers who were set on using them, Dylan taught them the more conservative ways to incorporate SARMs into their fitness regimen. This inclusive approach ensured that his viewers stayed as safe as possible.
In 2019, Dylan launched a new channel named "PE Fitness", which stands for "Performance Enhancement Fitness,” to continue his mission of educating enthusiasts about the proper way to reap the benefits offered by SARMs. The channel has garnered over 700,000 views since Dylan began uploading content in 2019. He also makes appearances on podcasts and contributes as a writer to popular bodybuilding and steroids websites such as Evolutionary.org. Readers can follow the Dylan Gemelli Facebook page to stay updated with all his content from across the web.
The PE Fitness channel has tons of videos discussing how to use and dose popular SARMs such as GW501516 (Cardarine), NPP, MK 677, Equipoise, YK11, MK2866 (Ostarine, Ostabolic), Turinabol, Trenbolone, RAD-140 Testolone, S23, Proviron, HGH Fragment 176-191, RAD140, and more. He also makes video guides answering his audience’s specific questions such as the best SARMs for fat burning, SARMs stacks, the best steroids for cutting, the best steroids for bulking, the best SARMs for strength, the best SARMs for endurance, the best steroids for muscle hardening, top-rated SARMs manufacturers, and more.
When asked about his vision for PE Fitness, Dylan Gemelli says, “PE Fitness aims to be the ultimate YouTube channel for everything related to performance enhancement. There is a lot of bad information out there being peddled by unscrupulous bloggers and unverified social media accounts that offer half-baked advice just to sell affiliate products. Unless you approach the study of SARMs systematically, not only will you not get any results but you may also end up damaging your body due to improper use. I realized that there was a need for a well-informed and knowledgeable voice in the industry, such as myself, who also has a high level of integrity. Subscribe to PE Fitness today to get the best performance enhancement, health, and fitness advice on the internet and to stay updated with the industry.”
Readers can also follow the Dylan Gemelli Twitter page where he posts daily inspirational quotes to spur his followers to change their lives.
For more information about Dylan Gemelli of P.E. Fitness, contact the company here: Dylan Gemelli of P.E. Fitness Dylan Gemelli 702-757-7727 dylangemelli@gmail.com Dylan Gemelli 15920 Hickman Road Ste 400 PMB 287 Clive, IA 50325
In June 2022, Athersys embarked on a financial and operational restructuring to lower its cost and conserve cash while completing the testing and commercialization of its adult stem-cell therapy.
Madrigal Pharmaceuticals' resmetirom is a leading treatment candidate for the advanced form of fatty liver disease.
IMV Inc (NASDAQ: IMV) announced preliminary data from the VITALIZE Phase 2B trial evaluating its lead DPX product, maveropepimut-S (MVP-S), in combination with Merck & Co Inc's (NYSE: MRK) Keytruda (pembrolizumab) for relapsed, refractory Diffuse Large B Cell Lymphoma (r/r DLBCL). Related: IMV's MVP-S Doublet Combo Therapy Shows Encouraging Anti-Tumor Activity 8 Patients with an ECOG score of 0-1 have been enrolled in arm 1 of the study. Of these, six have so far been evaluable for efficacy; Of
"Why? Why was I designed this way? Why do I have to be Bing Search?" the bot allegedly asked one user.
BioXcel Therapeutics Inc (NASDAQ: BTAI) announced full data from its Phase 2a trial of BXCL701 in combination with Merck & Co Inc's (NYSE: MRK) Keytruda (pembrolizumab) in small cell neuroendocrine (SCNC) variant metastatic castration-resistant prostate cancer (mCRPC) patients. The trial included patients after at least one prior line of chemotherapy for locally advanced or metastatic prostate cancer. In the evaluable patient cohort (n = 28), 7 (25%) patients achieved a composite response, the t
A handful of ads fumbled their chance to charm one of the biggest TV audiences of the year, marketing experts say.
Vir Biotechnology Inc (NASDAQ: VIR) has amended the research collaboration agreement established with GSK plc (NYSE: GSK) in 2020. Vir will continue its ongoing efforts to discover, develop and advance COVID-19 solutions and other potential coronavirus outbreaks, independently or with other partners. The companies will continue working to ensure ongoing access to sotrovimab for patients worldwide, where authorized, and to develop new therapies for influenza and other respiratory diseases. In Aug
CVS is becoming a dominant player beyond pharmacies. It's planned acquisition of Oak Street Health furthers that view.
A biopharmaceutical company in Research Triangle Park saw its stock get hammered Monday on news of disappointing clinical trial results for its lead cancer drug. G1 Therapeutics (Nasdaq: GTHX) announced Monday it has ended a phase 3 trial evaluating its lead drug, trilaciclib, in patients with metastatic colorectal cancer after the drug failed to outperform the placebo. The study was one of multiple clinical programs that G1 has underway as it tries to advance the drug, which is already approved for use in lung cancer.
Under Armour's newest athletic footwear won't squeak on a gym floor and has a collapsible heel to turn the sneaker into a slide
The billionaire entrepreneur enjoys shocking and provoking progressives he describes as the "woke mind virus."
Cockroaches and Armageddon. Why not?
The British pound has gone back and forth during the trading session on Monday, as we continue to see a lot of noisy behavior in general.
Blueprint's (BPMC) early- to mid-stage study for the treatment of patients with CDK2-vulnerable cancers put on partial clinical hold by the FDA.
Amazon has intentions of “doubling down” on its physical grocery business when the company lands on the format it likes, Andy Jassy indicated to the Financial Times.
The gene therapy company had aimed to start a clinical trial by the end of last year but laid off scores of employees, focused its work on two other programs and lost its founding CEO and chief medical officer.
The British pound has rallied a bit during the trading session after initially dipping lower against the Japanese yen.
(Bloomberg) -- Elon Musk had Twitter Inc. engineers working late on Sunday to alter his social network’s algorithm and prioritize his tweets, resulting in a glut of them in users’ feeds on Monday, according to a report by Platformer.Most Read from BloombergUS Says 3 Mystery Objects Likely Private, With No China LinkNew Cars Are Only for the Rich Now as Automakers Rake In ProfitsGunman Kills Three at Michigan State; Suspect Found DeadAmerica's Priciest Neighborhoods Are Changing as the Ultra-Rich
Abbott's (ABT) latest deal will help gain access to Cardiovascular System's leading atherectomy device to treat vascular disease.
The top five biotech stocks today have several commonalities: strong ratings. Some also show promising charts and are Tech Leaders.